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   CDSS  clinical decision support system 
COPD  chronic obstructive pulmonary disease 
CRS  chronic rhinosinusitis 
   CRSwNP  chronic rhinosinusitis with nasal polyps 
CRSsNP  chronic rhinosinusitis without nasal polyps 
CT  computed tomography 
EPOS European Position Paper on Rhinosinusitis and Nasal Polyps 
ESS  endoscopic sinus surgery 
GP  general practitioner 
HIT   health information technology 
ICP  integrated care pathway 
IT  immunotherapy 
MASK  MACVIA-ARIA sentinel network for rhinitis 
NP  nasal polyps 
   PM  precision medicine 
   OTC  over-the-counter 
   Qol  quality of life 
   VAS  visual analogue scale 
    
 
Abstract  
Precision medicine (PM) is increasingly recognized as the way forward for optimizing patient care. 
Introduced in the field of oncology, it is now considered of major interest in other medical domains 
like allergy and chronic airway diseases, which face an urgent need to improve the level of disease 
control, enhance patient satisfaction and increase effectiveness of preventive interventions. The 
combination of personalized care, prediction of treatment success, prevention of disease and patient 
participation in the elaboration of the treatment plan is expected to substantially improve the 
therapeutic approach for individuals suffering from chronic disabling conditions. Given the emerging 
data on the impact of patient stratification on treatment outcomes, European and American regulatory 
bodies support the principles of PM and its potential advantage over current treatment strategies.  
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The aim of the current document is to propose a consensus on the position and gradual 
implementation of the principles of PM within existing adult treatment algorithms for allergic rhinitis 
(AR) and chronic rhinosinusitis (CRS). At the time of diagnosis, prediction of success of the initiated 
treatment and patient participation in the decision of the treatment plan can be implemented. The 
second level approach ideally involves strategies to prevent progression of disease, in addition to 
prediction of success of therapy, and patient participation in the long-term therapeutic strategy. 
Endotype-driven treatment is part of a personalized approach and should be positioned at the tertiary 
level of care, given the efforts needed for its’ implementation and the high cost of molecular diagnosis 
and biological treatment.  
 
Introduction 
A new paradigm to advance medical care is Precision Medicine (PM) (1). The four Ps of PM stand for 
Personalized, Predictive, Preventive and Participatory. PM encourages a convergence of omics, 
systems medicine, innovative health information technology and consumer-driven healthcare. Global 
multidiscipline partnerships and the right balance between research and policy priorities are needed to 
achieve the audacious goal of PM. Applying the principles of PM at the point of care is one of the 
major challenges for development of the future healthcare system. 
PM is a medical model aiming at the customization of healthcare - with medical decisions, practices, 
and/or products tailored to the individual patient (2). Based on the knowledge of mechanisms of the 
disease, PM generally combines diagnosis and treatment to select optimal management (3,4).  
The concept of PM is not new. Clinicians have always observed that patients with similar symptoms 
may have different diseases, with different causes, and that treatment may have different outcomes 
depending on a multitude of individual external and endogenous factors. The novelty comes from the 
rapid technological advances, including omics, medical imaging, regenerative medicine, biobanks and 
registries, along with an increased computational power and innovative health information technology 
(HIT). This will allow real-time clinical decision support at the point of care with implementation of 
harmonized care based on quality criteria and patients to be treated and monitored more precisely and 
effectively to better meet their individual needs (2). In addition other providers will play a larger role 
in routine care for less complex cases and during follow-up. 
PM is rapidly gaining more attention in molecular diagnosis-based treatment of cancer (5) and other 
diseases. The practical implementation of PM is however more difficult in complex diseases such as 
multimorbid chronic diseases (3,6). Nonetheless, one recent example of successful application was 
reported in cystic fibrosis. In 4% of the patients, the specific intervention based on the molecular 
mechanism can totally reverse the disorder (7). In allergic diseases, PM principles have always been 
used, in particular for patients receiving allergen immunotherapy (AIT) (8). AIT is tailored to the 
patient’s sensitization profile and it has a long-lasting and preventive effect (9). Despite major 
advances in understanding allergic diseases, many patients with upper airway diseases are still 
uncontrolled (10,11) and primary prevention is still unknown. Recently, a PRACTALL report 
highlighted the need for PM in airway diseases (12).  
Chronic upper airway inflammation can be roughly divided into two major clinical entities, i.e. 
rhinitis and rhinosinusitis. The allergic phenotype is the best characterized phenotype of rhinitis from 
a pathophysiologic point of view (13). The diagnosis of allergic rhinitis (AR) requires the proof of 
IgE-mediated hypersensitivity using appropriate skin or blood tests and the implication of the relevant 
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allergen in eliciting the symptoms (14). Allergic and non-allergic rhinitis often co-exist but the 
treatment response differs (15), and many patients only use ‘over the counter’ (OTC) medications 
(16). Chronic rhinosinusitis (CRS) is classically divided into a phenotype with and without 
endoscopic or radiologic evidence of nasal polyps (CRSwNP and CRSsNP, respectively) (17).  
Both AR and CRS are characterized by inflammation, are divided into the mild, moderate and severe 
subgroups, and for both anti-inflammatory medication represents the first-line treatment (13,17,18). 
The use of nasal endoscopy and CT imaging may not be sufficient to fully appreciate the individual 
patients’ pathology. Endotyping of CRS on the basis of physiological, functional and pathological 
characteristics might provide information on the risk of disease progression or recurrence and on the 
best available treatments, and also helps in identifying innovative therapeutic targets for treatment 
(19). 
The Allergic Rhinitis and its Impact on Asthma (ARIA) treatment algorithms provide evidence-based 
guidelines for treatment of AR (13,20). Multiple treatment options, strategies and approaches can be 
applied depending on the level of control achieved or aiming for. In AR, AIT is recommended when 
pharmacotherapy is not successful, or as an alternative to long-term pharmacotherapy. Surgical 
reduction of the inferior turbinate(s) or correction of a septal deviation might be indicated when nasal 
obstruction persists as a major symptom in adequately medically treated AR patients. The European 
Position Paper on Rhinosinusitis and Nasal Polyps (EPOS) treatment algorithms provide evidence-
based guidelines for treatment of CRS (17). Anti-inflammatory medication in combination with saline 
douching represents the first step of treatment for CRS, with adaptation of the therapeutic regimen 
dependent on the degree of control (17). Surgery is considered if prolonged medical treatment fails, 
but up to 40% of patients remain symptomatic despite sinus surgery (21). 
Medical treatment for any condition aims at controlling the disease including clinically significant 
symptom reduction with improvement of quality of life and reduction of socio-economic impact of 
the disorder. In contrast to other diseases like asthma (22) and despite the high prevalence of AR and 
CRS (23,24), the concept of control of disease has only recently been introduced in AR (10,25) and 
CRS (17). However, this concept is important to define those patients with difficult-to-treat disease, 
representing a diagnostic and therapeutic challenge and having a large socio-economic burden 
(26,27). After defining those patients with uncontrolled disease, factors associated with lack of control 
can be identified, and better insights can be obtained in global airway disease control (28). Recently, 
uncontrolled disease in AR and CRS has been reported to reach 35% and 40% of patients treated in 
academic referral centers respectively, underscoring the need for novel and better strategies of care for 
both AR and CRS (21,29). Nowadays, it is clear that there is a need to optimize treatment and 
embrace the principles of PM in chronic airways diseases in order to achieve a higher level of control 
of disease.  
This review is an initiative taken by the non-profit EUFOREA leadership in conjunction with ARIA, 
EPOS, and AIRWAYS ICPs (16,17,30) (European Innovation Partnership on Active and Healthy 
Ageing, Action Group B3) experts who felt the need to provide a comprehensive overview of the 
current state-of-the-art on control in upper airway diseases, with a focus on the different factors 
involved in uncontrolled upper airway inflammation as well as the unmet needs in this domain. In 
addition, a proposal for gradual implementation of the principles of PM into the adult management 
algorithms of AR and CRS is made. 
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1- Gradual Implementation of the 4 principles of precision medicine in allergic rhinitis 
1-1- First-level management of AR  
AR is diagnosed based on the combination of a history of two or more nasal symptoms, nasal 
examination showing inflammatory changes in untreated patients and confirmation of the suspicion of 
sensitization by skin prick tests or specific IgE tests.  
At the time of the first diagnosis of AR in medical or specialist office, a therapeutic plan is elaborated 
taking into account the major presenting symptoms, the severity and impact of symptoms, 
comorbidities, and availability of treatment (Figure 1).  
At present, it seems clear that two key principles of PM can easily be implemented at the time of 
elaboration of a therapeutic plan (Figure 2): 
 Prediction of success of treatment:  
The treatment strategy may be guided using a recent algorithm proposed by worldwide 
experts (31). Physicians treating patients with AR should be aware of the different therapeutic 
strategies for AR and adapt to the patients’ profile (MACVIA-ARIA), preferences and needs, 
taking into account the availability and accessibility to the recommended treatment choice. 
Up to 50% of patients treated for AR want to be informed about the different treatment 
options and strategy applied at the time of diagnosis (32). Therefore, the following 
information on prediction of success of treatment on nasal, ocular, bronchial and general 
symptoms should be communicated to AR patients: 
o Information on the expected onset of action and benefit of treatment of different 
treatment options, both on symptom severity as well as on general functioning and 
quality of life 
o Information on the shortcomings, safety and potential adverse events of different 
treatment options and approaches 
o Information on the impact of treatment of AR on the comorbidities, like asthma, otitis 
media and eczema 
 
 Participation of the patient:  
Given the proven efficacy of several active compounds for AR, the different routes of 
administration of treatment, and the different aims of treatment, patients can be empowered to 
become an active partner in the elaboration of the following strategic choices for first-line 
treatment for AR (after receiving and understanding the above info): 
o Choice of oral versus nasal route of administration of effective molecules 
o Choice of combined treatment versus monotherapy 
o Choice of corticosteroidal versus non-corticosteroidal treatment options 
o Choice of pharmacological treatment versus allergen-specific immunotherapy 
Patient education is crucial in this process to allow patients to assess and self-monitor 
symptom severity and control, to properly use medication, and to be informed about whom to 
seek for medical advice.  
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After having elaborated a treatment strategy with the AR patient, it is recommended to evaluate the 
degree of symptom control regularly using mobile technology or after a time-interval of 2-4 weeks by 
physician’s visits. Symptom control in AR can be evaluated via different means, but a visual analogue 
scale (VAS) score seems to be a good tool for control evaluation in real clinical life (29,33,34). 
Telemonitoring enables convenient evaluation of patients on a regular basis. Clinical Decision 
Support Systems (CDSS), interactive computer software, is designed to assist health professionals 
with decision-making tasks, such as determining treatment strategies of patient using the results of 
ICPs. MASK (MACVIA-ARIA sentinel network for rhinitis) includes all these features (31,35,36). 
 
1-2- Second-level management of AR  
Following the initiation of first-line treatment, uncontrolled patients are invited for evaluation of 
symptom control and fine-tuning of the treatment strategy accordingly. Besides taking into account 
the achieved level of control by first-line treatment, a treatment strategy is elaborated according to the 
revised needs and expectations of the patient, the experienced efficacy and/or adverse events of the 
medication used, the availability of medication, and the long-term goal of maintaining or achieving 
disease control and prevent disease progression. 
Therefore, the following three key principles of PM can be implemented during the follow-up 
consultation for AR (Figure 2): 
 Prediction of success of any step-down or step-up approach, based on the input from the 
patient on the expected benefits 
 Participation of the patient in the management plan 
 Prevention of disease progression with clear statements on the different approaches for 
suppression of inflammation vs prevention of disease progression: 
o Secondary prevention aims at preventing the acquisition of new sensitizations and the 
onset of asthma in those AR patients who have not developed asthma yet. Evidence-
based therapeutic interventions for the secondary prevention of asthma fall into 3 
categories: 
 Pharmacological treatment 
 Allergen-specific immunotherapy (37) 
 Control of environmental allergens and cigarette smoke 
o Tertiary prevention aims at preventing irreversible damage to the inflamed organ, 
maximizing the remaining capabilities and functions of the organ. 
 
1-3- Third-level management of AR 
Following second-line treatment, uncontrolled patients are invited to attend outpatient clinics for 
evaluation and advise regarding long-term therapeutic strategy. At this stage, the majority of AR 
patients with uncontrolled disease are seeking specialist advice. At specialist level, a treatment plan 
should ideally be proposed according to the needs of the patient, the achieved level of control, the 
availability of medication and the long-term ambition.  
All four key principles of PM should be implemented during the follow-up consultation for AR at 
specialist level (Figure 2): 
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 Prediction of success of any step-down or step-up approach, with information on the expected 
benefits and risks of adverse events of long-term treatment 
 Participation of the patient in the therapeutic plan, with clear information on the goals and 
practical implications of different therapeutic strategies in the short- and long-term 
 Prevention of disease progression with clear statements on the different approaches for 
suppression of inflammation versus strategies for secondary (and tertiary) prevention of 
asthma. In occupational rhinitis, measures to prevent chronicity and development of asthma 
should be recommended, despite the major impact of the implementation. In AR, the 
sensitization pattern should guide the strategy for prevention of asthma, including the option 
of AIT. 
 Personalized care with a treatment plan proposed on the base of the major or most bothersome 
symptom(s), the comorbidities, the endotype (type 2 inflammation, mixed inflammation or 
neurogenic inflammation and barrier impairment), and the patients’ preferences, should be 
envisaged 
 
 
1-4-Integrated Care Pathways (ICPs) 
A large number of AR patients do not consult physicians because they think AR symptoms are normal 
and/or trivial whereas AR impacts social life, school and work productivity (13). Many AR patients 
use OTC drugs (16) and only a fraction have a medical consultation. The vast majority of patients 
visiting GPs or specialists have moderate/severe rhinitis (38–42). Integrated care pathways differ from 
practice guidelines as they are utilized by a multidisciplinary team and have a focus on the quality and 
co-ordination of care, thus corresponding ideally to the requests of PM implementation at the point-
of-care (43). An ICP is intended to act as a guide to holistic disease management in a stepwise and 
feedback manner. AIRWAYS ICPs have proposed a multisectoral care pathway for AR (Figure 3 
from (35)). 
 
 
2- Gradual Implementation of the 4 principles of Precision Medicine in CRS 
2-1- First-level management of CRS  
CRS diagnosis is based on the presence of two or more sino-nasal symptoms and either CT scan for 
non-otorhinolaryngologists, supplemented by allergy tests in case of suspicion of concomitant allergy, 
and/or nasal endoscopy by otorhinolaryngologists for phenotyping into CRS with and without nasal 
polyps (CRSwNP and CRSsNP).  
At the time of the first diagnosis of CRS in general or specialist practice, a therapeutic plan is 
elaborated taking into account the major presenting symptoms, the severity and impact of symptoms 
and comorbidities like asthma or chronic obstructive pulmonary disease (COPD)  (Figure 4) (44,45). 
First-line treatment can be considered by every clinician taking care of patients with CRS. 
 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
At present, it seems clear that the following two key parameters of PM can easily be implemented at 
the time of elaboration of a first therapeutic plan (Figure 5): 
 Prediction of success of treatment:  
Physicians treating patients with CRS should be aware of the different therapeutic modalities 
for CRS, involving nasal steroids, nasal douching, avoidance of exposure to cigarette smoke 
and (professional) irritants, and treatment of allergy in case of relevant sensitization and adapt 
to patient profile (EPOS), preferences and needs, taking into account the availability and 
accessibility to the recommended treatment choice.  
Therefore, the following information on prediction of success of treatment should be 
communicated to CRS patients: 
o Information on the expected onset of action and benefit of treatment of different 
treatment options, both on the symptom severity as well as on general functioning 
and quality of life 
o Information on the shortcomings, safety and potential adverse events of different 
treatment options and approaches 
o Information on the impact of treatment of CRS on the comorbidities, like asthma or 
COPD 
o Impact of exposure to irritants and allergens 
 Participation of the patient:  
Given the proven efficacy of different options for treatment of CRS, patients are empowered 
as active partners in the elaboration of the following strategic choices for first-line treatment 
for CRS: 
o Choice of combined nasal corticosteroid treatment with nasal douching, or mono-
therapy 
o Choice of concomitant treatment of comorbid allergy, asthma, or COPD  
Also in CRS patients, education is a crucial step in the process of patient participation. 
 
After having elaborated a treatment strategy with the CRS patient, it is recommended to evaluate the 
degree of symptom control after a time-interval of four weeks for patients with severe disease and 
three months for patients with mild-moderate disease.  
Symptom control in CRS can be evaluated preferably by the application of the EPOS criteria for 
control. It is estimated that up to 50% of patients with CRS still remain symptomatic, with partially 
controlled or uncontrolled CRS. The latter population is seen at specialist level, for fine-tuning the 
diagnosis and designing an optimal therapeutic plan. 
2-2- Second-level management of CRS  
Following the initiation of first-line treatment, uncontrolled CRS patients are invited for evaluation of 
the achieved level of symptom control and fine-tuning of the treatment strategy. Beside taking into 
account the achieved level of control by first-line treatment, a treatment strategy is elaborated 
according to the nasal endoscopic findings, the needs and expectations of the patient, the experienced 
efficacy and/or adverse events of the medication used, the availability of medication and the long-
term goal of maintaining or achieving disease control and/or secondary or tertiary prevention of 
disease. 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Therefore, the following key principles of PM can be implemented during the follow-up consultation 
for CRS (Figure 5): 
 Prediction of success of any step-down or step-up approach, with information of the patient 
on the expected benefits and risks of the chosen approach 
 Participation of the patient in the therapeutic plan, with clear explanation of the different 
treatment options for CRSwNP and CRSsNP, including (long-term) oral antibiotics and oral 
corticosteroids 
 Prevention of disease progression with clear statements on the different approaches for 
suppression of inflammation vs prevention of disease progression. 
o Secondary prevention in CRS aims to prevent the onset of asthma in those CRS 
patients who have not developed asthma symptoms or signs yet. Evidence-based 
therapeutic interventions for the secondary prevention of asthma fall into two 
categories: 
 Endoscopic sinus surgery (ESS): Recent evidence suggests that ESS may be 
associated with a reduced likelihood of developing asthma (46,47). 
 Control of exposure to environmental allergens and cigarette smoke is 
considered important in preventing the disease progression. Retrospective 
data have shown the impact of occupational exposure to low molecular 
weight irritants on the success of ESS (48,49). 
o Tertiary prevention aims to prevent irreversible damage to the inflamed organ, 
maximizing the remaining capabilities and functions of the organ. At this moment, 
tertiary prevention in CRS has not been studied. 
 
2-3- Third-level management of CRS  
Following second-line treatment, uncontrolled patients are evaluated for advices regarding long-term 
therapeutic strategy, including the position of ESS (29). At this stage, the majority of CRS patients 
with uncontrolled disease are seeking specialist advice. Specialists are supposed to fine-tune and 
reconsider the diagnosis in case of uncontrolled disease despite recommended treatment. At specialist 
level, a treatment plan should ideally be proposed according to the needs of the patient, the previously 
achieved level of control, the availability of medication and the long-term goal.  
 
All four key principles of PM should be implemented during the follow-up consultation for CRS at 
specialist level (Figure 5): 
 Prediction of success of medical versus surgical treatment, with information of CRS patients 
on the expected benefits of each approach on the short and long term, and the risks or adverse 
events of both approaches. ESS is successful for most disease parameters in CRS, including 
asthma control, but persistent inflammation and need for postoperative medical care need to 
be discussed with the patient (50). Also the balance between repetitive surgery, especially in 
patients with CRSwNP and the side effect of intensified medical treatment should be 
discussed (51). 
 Participation of the patient in the therapeutic plan, with clear information on the goals and 
practical implications of different therapeutic strategies on the short and long term, including 
post-operative care, importance of compliance to treatment regimes and avoidance of irritants. 
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 Prevention of disease progression with clear approaches for suppression of inflammation 
versus strategies for secondary prevention of asthma.  
 Personalized care with an endotype driven treatment plan, including biological treatment for 
CRSwNP, based on nasal inflammatory patterns (52). Indeed, recent evidence highlights the 
benefit of biological treatment in CRSwNP patients, with superiority over oral corticosteroid 
therapy (53–55). Easy to apply biomarkers are now needed to identify those patients who 
might benefit from biological treatment. 
 
Conclusions 
PM represents the way forward for improved care in patients with chronic upper airway inflammation, 
and for prevention of asthma in patients with rhinitis and rhinosinusitis. Despite the perception of 
being associated with high cost of molecular analyses and biological treatment, most principles of PM 
can already be implemented in first and secondary level management without major costs. Given the 
diverse nature of uncontrolled disease, even implementing three out of four principles of PM in 
routine care may lead to an increased degree of patient satisfaction, control of disease and prevention 
of asthma. AR patients may benefit from full control of disease with prevention of asthma, by the 
combination of regular pharmacotherapy and AIT. It is important to recognize that AR may be an 
optimal model to identify molecular causes for variable treatment response: AR is common, has a 
well-defined and accessible phenotype, and often known external triggers (allergens). The disease 
process can be mimicked in vitro and in vivo to define novel biomarkers and drug targets for PM. 
Despite the emerging evidence of biologicals being the future of CRSwNP care, the long-term 
benefits still need to be confirmed. In addition, future studies are needed to confirm the benefit of the 
proposed care strategy for AR and CRS on socio-economic level as well as on the level of patient 
satisfaction and control of disease. 
FIGURE LEGENDS 
Figure 1. Graded implementation of precision medicine in allergic rhinitis (adapted from Hellings et 
al. (11)). 
VAS: visual analogue scale, TNS: total nasal symptoms, IT: immunotherapy, AR: allergic rhinitis. 
Figure 2. Precision medicine implementation in allergic rhinitis. 
Qol: quality of life, AIT: allergen immunotherapy. 
Figure 3. Multisectoral care pathway for allergic rhinitis (from Bousquet et al. (35)). 
OTC: over-the-counter. 
Figure 4. Graded implementation of precision medicine in chronic rhinosinusitis (adapted from 
Hellings et al. (11)). 
CRSwNP: chronic rhinosinusitis with nasal polyps, CRSsNP: chronic rhinosinusitis without nasal 
polyps. 
Figure 5. Precision medicine implementation in chronic rhinosinusitis. 
ESS: endoscopic sinus surgery, Qol: quality of life. 
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